The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; PharmaMar; Takeda
Research Funding - AstraZeneca (Inst); Baxter (Inst); Celgene (Inst); Clovis Oncology (Inst); Heat Biologics (Inst); Incyte (Inst); Merck (Inst); Newlink Genetics (Inst); Stem CentRx (Inst)
Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.
 
Jyoti Malhotra
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - BeyondSpring Pharmaceuticals (Inst); Biohaven Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst)
 
Petros Nikolinakos
No Relationships to Disclose
 
Ticiana Leal
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BMS Brazil; Bristol-Myers Squibb; Genentech; Novartis; Takeda; Takeda
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Genentech; Genentech; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Novartis; Takeda; Takeda
 
Jonathan Lehman
Research Funding - Abbvie (Inst); Ipsen (Inst)
 
Daniel Morgensztern
No Relationships to Disclose
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Takeda Science Foundation
 
John M. Wrangle
No Relationships to Disclose
 
Giuseppe Curigliano
Honoraria - Ellipses Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung
Speakers' Bureau - Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech
 
Eric Dansin
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Roche
 
Laurent Greillier
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb
 
Melissa Lynne Johnson
Consulting or Advisory Role - Araxes Pharma (Inst); Astellas Pharma (I); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Incyte (Inst); Loxo (Inst); Merck (Inst); Mersana (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Foundation Medicine (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Incyte (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Syndax (Inst); Syndax (Inst); Tarveda Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; EMD Serono; Exelixis; Genentech; Incyte; Merck; Pfizer; Sysmex; Vapotherm
 
Neal Ready
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Merck; Novartis; Pfizer
 
Gilles Robinet
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Satwant Lally
Employment - Abbvie/Stemcentrx
Stock and Other Ownership Interests - Abbvie/Stemcentrx
 
Shekman Wong
Employment - Abbvie/Stemcentrx
Stock and Other Ownership Interests - Abbvie/Stemcentrx
 
Emin Avsar
Employment - Novartis Institutes for BioMedical Research
Stock and Other Ownership Interests - Novartis
 
Ricardo Valenzuela
Employment - Abbvie/Stemcentrx
Stock and Other Ownership Interests - Abbvie/Stemcentrx
 
Charity D. Scripture
Employment - Abbvie/Stemcentrx
Stock and Other Ownership Interests - Abbvie/Stemcentrx
 
Giovanni Selvaggi
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Biogen (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inivata (Inst); Ipsen (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Onxeo (Inst); Pfizer (Inst); PharmaMar (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); Tiziana Therapeutics (Inst)